NCT01948843View on ClinicalTrials.gov

Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

HER2 Negative Metastatic Breast Cancer

Interventions

DRUG

ADI-PEG 20

Trial Locations (1)

77230

M.D. Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Polaris Group

INDUSTRY